Clinical trials: Diabetes Type 2
Type 2 Diabetes, Mild Cognitive Impairment
Improving Medication Adherence in Older African Americans With Diabetes
This research aims to help older African Americans with diabetes and mild memory problems improve how they take their medications and control their diabetes.
- Trial name
- NCT02174562
- Testing
- Primary Care-Occupational Therapy, Enhanced Usual Care
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Thomas Jefferson University
Overweight, Obesity
Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.
- Trial name
- NCT02307279
- Testing
- Gelesis100
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 436 people
- Sponsor
- Gelesis, Inc.
Diabetes Mellitus
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous administration of exenatide once weekly (EQW) 2…
- Trial name
- NCT02229396
- Testing
- Exantide with Dapagliflozin, Exentide, Dapagliflozin
- Where
- 133 sites in United States, Hungary and 4 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Sub-optimal Vitamin D Status, Pre-diabetes
Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study
Insulin resistance is a state where the body does not respond as it should to the insulin it produces. Individuals who are insulin resistant are at increased risk of both heart disease and type 2 diabetes; importantly, diabetes…
- Conditions
- Sub-optimal Vitamin D Status, Pre-diabetes, Insulin Resistance
- Trial name
- NCT01889810
- Testing
- Vitamin D3 supplementation
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Type 2 Diabetes Mellitus, Obesity
Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
There is substantial clinical evidence regarding the safety and efficacy of currently practiced bariatric surgical techniques to improve metabolic control and/or resolve type 2 diabetes (T2DM) in clinically severe obese patients…
- Trial name
- SLIMM-T2D (NCT01073020)
- Testing
- Allergan Adjustable Gastric Band Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group, Roux-en-Y Gastric Bypass (RYGB) Surgery
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Joslin Diabetes Center
Type 2 Diabetes Mellitus
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a…
- Trial name
- NCT02738879
- Testing
- Sitagliptin, Metformin, Metformin XR
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes.
- Trial name
- NCT03922750
- Testing
- Insulin icodec, Insulin glargine U100
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 154 people
- Sponsor
- Novo Nordisk A/S
Diabetes
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
- Trial name
- NCT00313313
- Testing
- Saxagliptin, Glyburide, Metformin
- Where
- 115 sites in United States, Argentina and 11 more
- Volunteers
- 768 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Home-based Resistance Training to Patients With Type 2 Diabetes
The purpose of this study is to compare motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise (elastic band to non-elastic band) to improve physical activity, muscle strength…
- Trial name
- NCT04755660
- Testing
- Exercise behavior change for resistance exercise
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Diabetes Mellitus, Type 2
Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers
Metformin hydrochloride in its immediate release (IR) form has been successfully used for decades in the treatment of type 2 diabetes; however the IR formulation may be associated with gastrointestinal side effects (especially…
- Trial name
- NCT01561976
- Testing
- Metformin hydrochloride prolonged release, Metformin hydrochloride sustained release/Glimepiride
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at Month 6, Week 26) in participants with type 2 diabetes mellitus…
- Trial name
- EDITION III (NCT01676220)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 217 sites in United States, Bulgaria and 14 more
- Volunteers
- 878 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus.
- Trial name
- NCT04235959
- Testing
- Tirzepatide
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Angina Pectoris, Coronary Artery Disease
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- TERISA (NCT01425359)
- Testing
- Ranolazine
- Where
- 135 sites in United States, Belarus and 12 more
- Volunteers
- 949 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
The purpose of this study is to assess the efficacy and safety of sitagliptin/simvastatin fixed-dose combination (FDC) in participants with T2DM who have inadequate glycemic control while on metformin monotherapy.
- Trial name
- NCT01678820
- Testing
- Sitagliptin/Simvastatin FDC, Sitagliptin, Simvastatin
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Type 1, Diabetes, Type 2
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Safety in Diabetics with T/I
- Trial name
- NCT00308737
- Testing
- Technosphere® Insulin Inhalation Powder, Usual Care
- Where
- 176 sites in United States, Canada and 6 more
- Volunteers
- 2,053 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
Cognitive Training for Diabetes Self-Management
The overall objective of this study is to determine the effects of a comprehensive cognitive rehabilitation intervention on biological, cognitive, and diabetes self-management outcomes.
- Trial name
- NCT04831775
- Testing
- Memory, Attention, and Problem Solving Skills for Diabetes, Brain Games
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Diabetic Nephropathies
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
- Trial name
- NCT01200394
- Testing
- PF-00489791
- Where
- 160 sites in United States, Australia and 13 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
- Trial name
- NCT00673231
- Testing
- Dapagliflozin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 1,240 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes
This is an open-label, proof of concept study with a single active treatment arm designed to assess whether CVS-based stimulation has a beneficial effect on patients with type 2 diabetes.
- Trial name
- NCT02130401
- Testing
- TNM Device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Scion NeuroStim
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.